Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | MAOB | P27338 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 9/20 | 0.55 |
| ▸ | CA2 | P00918 | 9/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31747379 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL19243360 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL22511877 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL1930913 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL1328306 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31169524 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31169526 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL963880 | 0.98 | MAOA (0.71) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL14086303 | 0.94 | MAOA (0.66) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL4967290 | 0.93 | MAOA (0.68) | MAOAMAOBTDP1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149093-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| EP-4212552-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2023-07-19 | — | — | EP | disclosed |
| CN-110526933-B | Biotin variants, streptavidin mutants and use thereof | 赛威德医疗公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-108752439-B | Biotin variants, streptavidin mutants and uses thereof | 赛威德医疗公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-3466976-B1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| WO-2001005748-A1 | OLIGOMERIC AMINO ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | MONSANTO COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | NGLY1, ELOVL6, ELOVL1 | MAOA 2208/4885MAOB 2216/4885TDP1 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.